Prof Dr. Tao Sun | Nucleic Acid Drug | Best Researcher Award

Posted on by Pencis

Prof Dr. Tao Sun | Nucleic Acid Drug | Best Researcher Award

Nankai University | China

Author Profile

Scopus

Orcid ID

πŸ“š Prof. Tao Sun: Innovator in Oncology and Drug Development

πŸŽ“Position:

  • Professor and Doctoral Supervisor, College of Pharmacy, Nankai University, China πŸŽ“

🌟Titles and Awards:

  • National Youth Talent 🌟
  • Winner of the Tianjin Distinguished Youth Scholar πŸ†

πŸ”¬Research Focus:

  • Molecular mechanisms of malignant tumors 🧬
  • Drug development πŸ’Š
  • Pharmacology πŸ”¬

πŸ“„Publications:

  • Over 40 papers in prestigious journals, including Advanced Materials, Science Translational Medicine, Hepatology, and Cancer Research, as the first or corresponding author. πŸ“„

πŸ“œPatents and Approvals:

  • More than 20 authorized patents πŸ“œ
  • 3 new drug clinical approvals βœ…

πŸ§ͺResearch Leadership:

  • Principal investigator of 8 major scientific research projects, including Major National Science and Technology Projects and general projects of the National Natural Science Foundation of China. πŸ§ͺ

πŸ₯‡Achievements in Education:

  • Instructed students to win the Gold Award in the China International College Students’ “Internet+” Innovation and Entrepreneurship Competition πŸ₯‡
  • Recipient of the “Top Ten Award of Scholarly Mentor and Beneficial Friend” at Nankai University πŸŽ–
  • Second Prize winner of the Nankai University Teaching Achievement Award πŸ₯ˆ

πŸ’ŠSummary:

  • Prof. Tao Sun is a distinguished scholar and innovator at Nankai University, renowned for his contributions to oncology, drug development, and pharmacology. His prolific research, numerous patents, and leadership in significant scientific projects underscore his impact in the field. As an educator, he has been instrumental in guiding students to achieve excellence, earning recognition for his mentorship and teaching achievements. πŸŒŸπŸ”¬πŸ’Š

 

πŸ“ŠπŸ”¬Notable Publication:

 

Interaction between laminin-5Ξ³2 and integrin Ξ²1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins

  • Authors: Zhou, B., Zong, S., Zhong, W., … Sun, T., Liu, Y.
    Journal: Oncogene
  • Year: 2020

 

Glycyrrhizic Acid-Induced Differentiation Repressed Stemness in Hepatocellular Carcinoma by Targeting c-Jun N-Terminal Kinase 1

  • Authors: Cai, S., Bi, Z., Bai, Y., … Liu, H., Yang, C.
    Journal: Frontiers in Oncology
  • Year: 2020

 

Twist1-YY1-p300 complex promotes the malignant progression of HCC through activation of miR-9 by forming phase-separated condensates at super-enhancers and relieved by metformin

  • Authors: Meng, J., Han, J., Wang, X., … Liu, H., Sun, T.
    Journal: Pharmacological Research
  • Year: 2023

 

Correction: Interaction between laminin-5Ξ³2 and integrin Ξ²1 promotes the tumor budding of colorectal cancer via the activation of Yes-associated proteins

  • Authors: Zhou, B., Zong, S., Zhong, W., … Sun, T., Liu, Y.
    Journal: Oncogene
  • Year: 2020

 

YY1 complex promotes quaking expression via super-enhancer binding during EMT of hepatocellular carcinoma

  • Authors: Han, J., Meng, J., Chen, S., … Sun, T., Yang, C.
    Journal: Cancer Research
  • Year: 2019

Dr. Lei Xia | Theranostics | Best Researcher Award

Posted on by Pencis

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |Β  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD 🧬

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
πŸ“ž Phone: 18811177191
βœ‰οΈ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes 🩻
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes 🧫
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes πŸ§ͺ
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) 🌟
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) 🌟
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) 🌟
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund 🌟
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund 🌟
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital 🌟
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund 🌟
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

πŸ“ŠπŸ”¬Notable Publication: